Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2014

View Archived Issues

Doxofylline receives FDA orphan drug status for bronchiectasis

ONC1-13B shows high efficacy in preclinical models of prostate cancer

ProTide technology applied to anticancer agents to overcome drug resistance

BioAtla grants BioMotiv worldwide rights to IL-22 antibody

Pivotal trial of LDE-225 in advanced basal cell carcinoma meets primary endpoint

CURx Pharmaceuticals enters into license agreement with Gilead Sciences

Phase III ramucirumab lung cancer trial meets primary endpoint of overall survival

Zealand Pharma prepares novel glucagon receptor agonists

Insmed provides interim update from extension study of Arikace in cystic fibrosis

Omeros doses first patient in second phase II trial of OMS-824

Oritavancin NDA accepted by FDA for filing

Researchers at Proximagen present new PAR-2 antagonists

Preclinical results presented for RTL-1000 as a therapeutic agent for stroke

Actavis to acquire Forest Laboratories

Cellceutix submits IND for Prurisol trial, begins enrollment in phase IIb trials of brilacidin

Onconova discloses results from phase III trial of intravenous rigosertib in higher risk MDS

Nerviano Medical Sciences discloses novel JAK inhibitors

Michael J. Fox Foundation awards grant to Ezose Sciences

New H+/K+-ATPase inhibitors designed for gastrointestinal and other disorders

Bayer begins phase III COAST trial of regorafenib

Korean group prepares novel MAbs for cancer

PAK-01 enhances reperfusion and neuroprotection with no hemorrhagic transformation in vivo

Dilafor and Lee's Pharmaceutical sign license agreement for tafoxiparin in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...